Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCommunity Health Plan WA GJB2/GJB6 Coverage | Open…
    Ask Trek AI about this page
    CurrentCommunity Health Plan WashingtonPolicy N/A

    Genetic testing for hereditary hearing loss (GJB2/GJB6 sequencing, deletion/duplication, and multigene panels)

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria for GJB2 and GJB6 sequencing/deletion-duplication analysis and multigene panel testing to diagnose hereditary (syndromic or nonsyndromic) hearing loss for members of the health plan.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGenetic testing for hereditary hearing loss (GJB2/GJB6 sequencing, deletion/duplication, and multigene panels)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewApr 24, 2024
    Next Review DateApr 24, 2025
    Key ActionObtain GJB2/GJB6 testing first or a multigene panel that includes GJB2/GJB6 when evaluating suspected hereditary hearing loss and ensure no acquired cause is present.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50%proportion of autosomal recessive hereditary hearing loss due to GJB2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    70-80%
    proportion of genetically determined nonsyndromic hearing loss
    ACMG 2022guideline referenced
    Investigationaltesting outside criteria

    Coverage Criteria

    Medically necessary testing criteria

    Covered when ALL of the following are met

    GJB2/GJB6 or multigene panel medical necessity: (A) The member/enrollee has hearing loss; AND (B) There is no known acquired cause of the hearing loss (e.g., TORCH infections, bacterial infection, age-related or noise-related hearing loss).

    Tests specified include GJB2 sequencing and/or deletion/duplication (81252, 81479) and/or GJB6 sequencing and/or deletion/duplication (81479) or multigene panel analysis (81430, 81431, 81254).

    Investigational indications

    Investigational: GJB2/GJB6 sequencing and/or deletion/duplication analysis or multigene panel analysis is considered investigational for all other indications not meeting the above criteria.

    Testing is considered investigational for indications other than establishing a diagnosis of hereditary hearing loss in a person with hearing loss and no known acquired cause. The policy specifies that GJB2 and GJB6 sequencing and/or deletion/duplication analysis or multigene panel analysis is medically necessary only when the member has hearing loss and there is no known acquired cause (for example, TORCH infections, bacterial infection, age-related or noise-related hearing loss). For any other clinical indication, testing is considered investigational and may be denied.

    Covered Indications

    Diagnosis of hereditary hearing loss in a member with hearing loss and no known acquired cause

    Diagnosis of hereditary hearing loss in a member with hearing loss and no known acquired cause: GJB2 and GJB6 testing options include sequencing and/or deletion/duplication analysis (e.g., CPTs 81252, 81479) or multigene hearing-loss panel analysis (e.g., CPTs 81430, 81431, 81254).

    Coding

    Example Covered/Referenced CPT CodesCPT
    81252GJB2 gene sequencing (example listed)
    81479Unlisted molecular pathology procedure / Multigene panel (example listed)
    81430Hearing loss panel (example listed)
    81431Hearing loss panel, expanded (example listed)
    81254GJB6 common variant analysis (example listed)
    Example ICD-10 CodesICD-10
    H90-H90.8Hearing loss diagnosis code range (example)
    H90.A-H90.A3Hearing loss diagnosis codes (example)
    H91.3-H91.93Other hearing loss diagnosis code range (example)

    Provider Actions & Billing Guidance

    Documentation Required

    Coding and test documentation

    Providers should reference current coding guidance and submit claims using the most up-to-date CPT and ICD coding. The tests, associated laboratories, CPT codes, and ICD codes shown in the policy are examples for informational purposes and are not comprehensive or a guarantee of coverage. For a comprehensive, registered list of tests and their billing codes, consult the Concert Platform prior to claim submission.

    • Example CPTs referenced in this policy include: 81252 (GJB2 sequencing), 81479 (unlisted molecular pathology procedure), 81254 (GJB6 common variant analysis), 81430/81431 (large gene panels) — providers must verify current code applicability.
    • Inclusion or exclusion of codes in this policy does not ensure coverage; always confirm coding and coverage rules with the payer and lab-specific reporting.
    Step Therapy

    Recommended stepwise testing approach

    If there is not a high suspicion for a specific gene etiology, a stepwise testing approach is reasonable. Two medically acceptable strategies are: start with targeted testing of GJB2 and GJB6 (including sequencing and deletion/duplication analysis) and proceed to a comprehensive multigene panel if those tests are negative; OR begin with a multigene panel that includes GJB2 and GJB6 as the initial test. Given the heterogeneity of hereditary hearing loss, these strategies may be considered reasonably equivalent.

    Eligibility Requirements

    This policy does not impose additional eligibility filters beyond the primary clinical criteria. Coverage is determined based on meeting the diagnostic criteria for hereditary hearing loss (hearing loss with no known acquired cause) and the specified testing types (GJB2/GJB6 sequencing and/or deletion/duplication analysis or a multigene hearing loss panel). Family history or other top-level eligibility nodes are not required by this policy.

    There are no separate top-level eligibility requirements specified in this policy document. Decisions about testing eligibility should be made by confirming the member meets the covered indication—that is, presence of hearing loss with no known acquired cause—and that the requested test is one of the supported test types (single-gene GJB2/GJB6 testing or an appropriate multigene hearing loss panel).

    Not Covered

    Genetic testing for indications other than the diagnosis of hereditary hearing loss in a member with hearing loss and no known acquired cause is not covered (considered investigational). This includes requests where an acquired etiology has not been excluded or where the clinical indication does not align with the policy’s defined covered indication; such requests may be denied as investigational.

    Background

    Hereditary hearing loss may be syndromic (occurring with other clinical findings) or nonsyndromic (hearing loss without other physical signs). Nonsyndromic hearing loss accounts for approximately 70%–80% of genetically determined deafness, and the genetic causes are highly heterogeneous. The DFNB1 locus, which includes the GJB2 and GJB6 genes, accounts for an estimated ~50% of autosomal recessive nonsyndromic hearing loss. Before ordering genetic testing, evaluation should exclude acquired causes of hearing loss (for example, TORCH infections, bacterial infection, age-related or noise-related loss). For suspected autosomal recessive congenital/prelingual hearing loss, a stepwise approach is reasonable: begin with GJB2 and GJB6 testing and proceed to a multigene panel if negative, or alternatively obtain a multigene panel that includes GJB2/GJB6 as the first step.

    Definitions

    Nonsyndromic hearing loss
    DefinitionHearing loss not associated with other physical signs or symptoms.
    Prevalence among genetic casesAccounts for 70%–80% of genetically determined deafness.
    Diagnostic challengeBecause nonsyndromic cases lack other clinical findings, it is often more difficult to determine whether the etiology is hereditary or acquired.
    Clinical implicationEvaluation should exclude acquired causes (e.g., TORCH infections, noise, age-related) prior to or alongside genetic testing.
    DFNB1 locus
    DefinitionGenetic locus that includes GJB2 (connexin 26) and GJB6 (connexin 30).
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGenetic testing for hereditary hearing loss (GJB2/GJB6 sequencing, deletion/duplication, and multigene panels)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewApr 24, 2024
    Next Review DateApr 24, 2025
    Key ActionObtain GJB2/GJB6 testing first or a multigene panel that includes GJB2/GJB6 when evaluating suspected hereditary hearing loss and ensure no acquired cause is present.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider Actions & Billing GuidanceEligibility RequirementsNot CoveredBackgroundDefinitions
    • Stepwise option A: Perform GJB2 and GJB6 sequencing and deletion/duplication analysis first; if results are negative and clinical suspicion for hereditary hearing loss remains, proceed to a multigene panel.
    • Stepwise option B: Perform a multigene panel (that includes GJB2 and GJB6) as the initial test for suspected autosomal recessive or autosomal dominant hereditary hearing loss.
    Contribution to autosomal recessive HL
    Estimated to account for about 50% of autosomal recessive nonsyndromic hearing loss (DFNB1 locus).
    Population impactAccounts for an estimated 15%–40% of deaf individuals across various populations.
    Testing relevanceGJB2 and GJB6 are commonly included in single-gene testing strategies or multigene hearing-loss panels per guideline recommendations.